[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 34.204.52.4. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Editorial
December 12, 2017

Menopausal Hormone Therapy for Primary Prevention of Chronic Disease

Author Affiliations
  • 1Division of Preventive Medicine, Department of Medicine, University of Alabama at Birmingham School of Medicine, Birmingham, Alabama
  • 2Division of Diabetes, Endocrinology and Metabolism, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee
JAMA. 2017;318(22):2187-2189. doi:10.1001/jama.2017.16974

In this issue of JAMA, the US Preventive Services Task Force (USPSTF) presents a Recommendation Statement1 and an accompanying Evidence Report2 that consider the risks and benefits of menopausal hormone therapy for primary prevention of chronic conditions and arrive at a grade D recommendation.1 The recommendations are based only on evidence from randomized trials and do not pertain to women considering hormone therapy for vasomotor symptoms, given the USPSTF mandate to consider specific preventive care services for patients without related signs and symptoms of illness.

×